Peptide stacks
The Glow, Klow, Wolverine and Hulk stacks, and six more named combinations, each assessed on the evidence for the combination itself, not for its parts.
The finding, up front
Not one of these ten stacks is backed by a controlled human trial of the combination. Only two have been tested at all, and both results cut against the marketing: a 2026 rat study found BPC-157 and TB-500 together no better than either alone, and the epitalon report is a single unrepeated study from the people who sell it. Evidence for single compounds does not carry over, because the doses, the interactions and the blood levels of these combinations have never been measured, and side effects add up even where benefits do not. The phrase "for research use only" on a vendor's label is a legal shield, not a safety rating.
What a stack really is
Press play and Helen talks you through what these blends actually are, why combining compounds multiplies the unknowns, and how to read the evidence honestly, one component at a time.
At a glance
| Stack | Compounds | Evidence for the combination |
|---|---|---|
| Wolverine Stack (BPC-157 + TB-500) | 2 | Some combination data |
| Glow Stack (BPC-157 + TB-500 + GHK-Cu) | 3 | No combination trials |
| Klow Stack (GHK-Cu + KPV + BPC-157 + TB-500) | 4 | No combination trials |
| Hulk Stack (CJC-1295 with DAC + ipamorelin) | 2 | Some combination data |
| Modified GRF (1-29) + Ipamorelin (the no-DAC GH-pulse stack) | 2 | No combination trials |
| Tesamorelin + Ipamorelin (GH-axis fat loss stack) | 2 | No combination trials |
| GLP-1 Agonist + BPC-157 (the 'GLP-1 support' stack) | 4 | No combination trials |
| Semax + Selank (nootropic / anxiolytic stack) | 2 | No combination trials |
| Epitalon + Thymalin (pineal-thymic 'bioregulator' longevity stack) | 3 | Some combination data |
| Melanotan-II + Bremelanotide (melanocortin stack) | 2 | No combination trials |
Why component evidence does not transfer
Two compounds that each do something individually may do nothing extra together, may interfere, or may add risk without adding benefit. Ratios are unvalidated, there is no pharmacokinetic data for co-administration, and adverse effects can compound even where benefits do not. The one named stack anyone has actually tested in a controlled experiment (BPC-157 with TB-500) showed no advantage over either compound alone.
Wolverine Stack (BPC-157 + TB-500)
Some combination dataThe best documented stack here, and the documentation argues against it. A 2026 rat study tested the two peptides together and found no extra benefit over either one alone.
The claimed rationale
Named after the comic book character who heals fast, this pairs two repair peptides in the hope that one works on the injury site while the other works on the whole body. That division of labour is a community idea, not something anyone has demonstrated.
What evidence exists for the combination
A 2026 rat study tested BPC-157 alone, TB-500 alone and the two together on Achilles tendon healing, and the pair was no better than either one on its own (Bicer and colleagues, PMID 42542926). There are no human trials of the combination, and the human trials people quote for TB-500 actually used the full natural protein, thymosin beta-4, not the short fragment sold under that name.
Risks and unknowns
Both push the body to grow new blood vessels, which is the hoped for benefit and also the main unanswered safety question, because that growth is not aimed only at injured tissue. Nobody has measured what the two do to each other in the body, and there is no tested dose ratio. Both are banned in sport at all times, and in 2023 the US FDA placed both in its category for substances that pose significant safety risks.
Assessment: Tier 1: animal combination data exists and was negative for additivity; no human combination data
Glow Stack (BPC-157 + TB-500 + GHK-Cu)
No combination trialsNo trial has ever tested these three compounds together, in people or animals. The GHK-Cu research people quote is all about cream rubbed on skin, not injections.
The claimed rationale
The Wolverine pair plus GHK-Cu, a copper carrying peptide sold for skin, hair and looks. The claim is that the first two repair tissue while GHK-Cu rebuilds collagen, which shifts the whole thing from treating injury to cosmetics.
What evidence exists for the combination
No study has tested these three together, in people or in animals. Every controlled human trial of GHK-Cu used it as a cream on the skin, so none of that research tells you what happens when it is injected.
Risks and unknowns
Injecting copper skips the controls in your gut that normally stop you taking on too much of it, and nobody has measured how much builds up or what it does to the liver. Three unapproved compounds together means no interaction data, no blood level data and no tested ratio. Two of them are banned in sport and were placed by the US FDA in its category for substances that pose significant safety risks.
Assessment: Tier 0: no combination data of any kind, human or animal
Klow Stack (GHK-Cu + KPV + BPC-157 + TB-500)
No combination trialsA four compound stack with no combination study in people or animals. KPV has never been tested in a human trial, and its best known result used an engineered delivery capsule rather than the peptide as sold.
The claimed rationale
KPV, a small anti-inflammatory piece of a natural hormone, added to the Glow Stack. The claim is that calming inflammation lets the repair peptides do their job, which sounds sensible and has never been tested.
What evidence exists for the combination
Nothing has tested these four together, in people or in animals. KPV has no human trials at all, and its best known animal result relied on an engineered nanoparticle capsule to carry it into the gut, not the plain peptide as sold.
Risks and unknowns
Four unapproved compounds make six possible pairings, none of them studied, so if you feel better or worse there is no way to tell which one did it. KPV has no human safety data of any kind and no established dose range. Damping inflammation while also driving growth and new blood vessels is a mix whose net effect on infection risk and unwanted tissue growth has never been measured.
Assessment: Tier 0: no combination data of any kind; one component has no human data whatsoever
Hulk Stack (CJC-1295 with DAC + ipamorelin)
Some combination dataThe only stack with a real mechanism behind it, since these two drug types genuinely release more growth hormone together than apart in humans. But that was shown with different molecules in one off laboratory tests, and nobody has ever trialled this exact pair.
Components
The claimed rationale
Two growth hormone boosters that press different switches on the pituitary gland, so together they release more than either does alone. This is the one stack whose logic comes from published human physiology rather than marketing.
What evidence exists for the combination
That double switch effect is real in people, but it was shown with different drugs, in single laboratory sessions, measuring only the immediate hormone rise (Veldhuis and colleagues, PMID 19240251). No trial has ever given CJC-1295 with DAC alongside ipamorelin, and both compounds were abandoned by the companies developing them.
Risks and unknowns
If two drugs amplify each other's effect they amplify each other's risk too, and the DAC version lasts about a week, so exposure cannot be pulled back quickly if something goes wrong. Keeping growth hormone and IGF-1 raised for long stretches is the pattern behind higher blood sugar, fluid retention, joint pain and carpal tunnel syndrome, and over many years in people with natural hormone excess, heart disease and more cancer. Both are banned in sport at all times, and in 2023 the US FDA placed both in its category for substances that pose significant safety risks.
Assessment: Tier 2: human acute mechanistic data supports GHRH-plus-GHRP synergy as a drug class, but no trial has tested this specific pairing or any chronic outcome
Modified GRF (1-29) + Ipamorelin (the no-DAC GH-pulse stack)
No combination trialsA more physiologically thoughtful version of the Hulk Stack, aiming for hormone bursts instead of a constant rise. It has no trial evidence at all, and its main ingredient never entered clinical development.
Components
The claimed rationale
The Hulk Stack idea with a short acting booster, so growth hormone comes in a burst rather than staying up for days. People often dose at bedtime to copy the body's natural night time surge, which is thoughtful reasoning rather than evidence.
What evidence exists for the combination
No trial has tested this pair, and the short acting GHRH analogue sold for it never went through clinical development, so it has almost no published human data of its own. The synergy studies people point to used different molecules and measured only the immediate hormone rise.
Risks and unknowns
Everything in the Hulk Stack applies except the week long stay in the body, and repeated bursts still raise IGF-1 over time, bringing the same higher blood sugar, fluid retention and joint pain. Nobody has measured the hormone pattern these two actually produce together, so the idea that bursts are safer is an assumption. Because this GHRH analogue never had a clinical programme there is no reference standard for the material, and testing of grey market versions has repeatedly found identity and purity problems.
Assessment: Tier 0: no combination data; supporting synergy data is for different molecules and acute endpoints only
Tesamorelin + Ipamorelin (GH-axis fat loss stack)
No combination trialsUsing an approved medicine does not make the combination evidence based. Tesamorelin was only ever trialled on its own, in people with HIV related fat changes, and never alongside ipamorelin.
Components
The claimed rationale
This swaps in tesamorelin, a genuinely approved medicine for excess belly fat in people with HIV related fat changes, and adds ipamorelin to push growth hormone higher still. It is promoted for body recomposition to people who do not have that condition.
What evidence exists for the combination
No study has ever given these two together. Tesamorelin's real trial record is all single drug and in specific patient groups, and using an approved medicine next to an unapproved one does not lend the pair that evidence.
Risks and unknowns
The approved ingredient creates a false sense of safety: tesamorelin was tested alone, at set doses, in one patient group, and the point of the stack is to push hormone levels past where it was tested. Its known problems are the ones that get worse here: rising blood sugar and diabetes, fluid retention, joint pain, carpal tunnel syndrome and injection site reactions. Because IGF-1 encourages cells to grow, this should never be used by anyone with active cancer, and community protocols include none of the screening or blood tests that proper medical use would involve.
Assessment: Tier 0: no combination data; one component has genuine single-agent approval evidence in a population unlike most users
GLP-1 Agonist + BPC-157 (the 'GLP-1 support' stack)
No combination trialsA fast spreading modern combination with no supporting evidence at all. Nothing has tested whether the added peptides protect muscle, and using BPC-157 to mask gut side effects could hide something serious.
Components
The claimed rationale
Weight loss injections take some muscle along with the fat, so people add BPC-157 and sometimes a growth hormone booster hoping to hold on to muscle. BPC-157 is also sold as a way to settle the nausea and gut upset those injections cause.
What evidence exists for the combination
No trial has tested any version of this mix. The weight loss drugs have large, high quality trials on their own, but nothing has ever tested whether BPC-157 or ipamorelin protects muscle in a human being.
Risks and unknowns
Putting unapproved compounds alongside a medicine that needs proper medical supervision encourages people to manage it themselves. Using BPC-157 to settle gut symptoms is untested and may be dangerous, because those same symptoms are how pancreas and gallbladder problems show up, and masking them delays diagnosis. Adding a growth hormone booster raises blood sugar, working directly against the reason for taking the weight loss drug in the first place.
Assessment: Tier 0: no combination data; the lean-mass-preservation premise is untested for the added components
Semax + Selank (nootropic / anxiolytic stack)
No combination trialsThe most used brain peptide pairing has no combination study whatsoever. The research on each one sits almost entirely in Russian language journals, unregistered and rarely repeated elsewhere.
The claimed rationale
Two Russian brain peptides paired so that one sharpens focus and the other takes the edge off it. Both are registered medicines in Russia and nowhere in the West.
What evidence exists for the combination
No study has given them together and measured thinking or anxiety. Their whole clinical literature sits in Russian language journals outside the international trial registers, and independent groups have barely repeated any of it.
Risks and unknowns
Both are usually sprayed up the nose, where absorption varies a lot, so nobody can say how much actually gets in. Semax is built from a piece of a stress hormone and Selank from an immune signalling one, and neither has been checked for what repeated use does to those systems in people. Mood and focus are exactly what placebo affects most, so personal reports about this stack carry very little weight.
Assessment: Tier 0: no combination data; single-agent literature is largely unreplicated outside its country of origin
Epitalon + Thymalin (pineal-thymic 'bioregulator' longevity stack)
Some combination dataThe only stack with a published human combination study, and it is one unrepeated report from the people who developed and sell the products. It also used animal tissue extracts rather than the synthetic epitalon on sale now.
The claimed rationale
A longevity pairing from a Russian research programme, built on the idea that the pineal gland and the thymus both fade with age and should be restored together. It is the only stack here whose combination claim has a published human report behind it.
What evidence exists for the combination
That report claims fewer deaths among elderly patients, but it was not randomised, blinded or registered, it came from the institution that sells the products, and nobody has repeated it in more than twenty years (Khavinson and Morozov, 2003, PMID 14523363). It also used peptide preparations extracted from animal tissue, not the synthetic epitalon sold today, so it does not describe what people are actually buying.
Risks and unknowns
A claim about people living longer sounds powerful, but a single unrepeated report from the seller cannot support it. Preparations made from animal tissue bring immune reaction and contamination concerns, and synthetic epitalon has no human safety trial and no long term data at all. The much repeated telomerase claim is not a selling point either, because switching that enzyme back on is one of the steps cells take towards becoming cancer, and what it does long term in people is unknown.
Assessment: Tier 3: human combination data exists but is single-source, unreplicated, methodologically inadequate, and used different substances from those sold today
Melanotan-II + Bremelanotide (melanocortin stack)
No combination trialsIncluded as a cautionary entry. Bremelanotide is what melanotan-II becomes in the body, so this doubles up on the same receptors, and melanotan-II is unapproved everywhere and carries regulator warnings.
Components
The claimed rationale
Combined for a tan and for sexual effects at the same time. What most users miss is that one of the two is simply what the other turns into inside the body.
What evidence exists for the combination
No trial has tested the pair, and there is a good reason nobody would design one: bremelanotide is the active breakdown product of melanotan-II, so this stacks a drug with its own metabolite at the same receptors. Bremelanotide is an approved medicine with real trials behind it, while melanotan-II has never been approved anywhere and has drawn repeated safety warnings from national medicines regulators.
Risks and unknowns
Both act on the same receptors, so side effects add up by design: nausea, flushing, headache and a short lived rise in blood pressure, which is why bremelanotide carries cautions for heart disease and uncontrolled high blood pressure. Melanotan-II darkens existing moles and can bring new ones, and there are published cases of melanoma in users, so the expected effect and the main warning sign of skin cancer look the same and checking yourself becomes unreliable. There is no dosing or interaction data for the pair, so users have no way to judge their total exposure.
Assessment: Tier 0: no combination data; combining a compound with its own active metabolite has no coherent rationale